DOCSLIB.ORG

Monografía SERAM Medios De Contraste En Radiología Libro SERAM-2007 13/11/07 12:40 Página II Libro SERAM-2007 13/11/07 12:40 Página III

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monografía SERAM Medios De Contraste En Radiología Libro SERAM-2007 13/11/07 12:40 Página II Libro SERAM-2007 13/11/07 12:40 Página III Libro SERAM-2007 13/11/07 12:40 Página I Monografía SERAM Medios de contraste en Radiología Libro SERAM-2007 13/11/07 12:40 Página II Libro SERAM-2007 13/11/07 12:40 Página III Monografía SERAM MediosMedios dede contrastecontraste enen RadiologíaRadiología Coordinadores: Luis Martí-Bonmatí Yolanda Pallardó Calatayud EDITORIAL MEDICA BUENOS AIRES - BOGOTÁ - CARACAS - MADRID - Sociedad Española de MÉXICO - PORTO ALEGRE Radiología Médica www.medicapanamericana.com Libro SERAM-2007 14/11/07 08:49 Página IV Catalogación en Publicación de la Biblioteca Nacional Medios de contraste en radiología / coordinadodres, Luis Martí-Bonmatí, Yolanda Pallardó Calatayud — Buenos Aires ; Madrid : Médica Panamericana, cop. 2008 [i.e. 2007] VIII, 160 p. : il. ; 28 cm — (Monografía SERAM) En la port.: Sociedad Española de Radiología Médica = Incluye referencias bibliográficas e índice ISBN 978-84-7903-899-1 1. Sustancias de contraste. I. Martí-Bonmatí, Luis. II. Pallardó Calatayud, Yolanda 615.033 La Medicina es una ciencia en permanente cambio. A medida que las nuevas investigaciones y la experiencia clínica amplían nuestro conocimiento, se requieren modificaciones en las modalidades terapéuticas y en los tratamientos farmacológicos. Los autores de esta obra han verificado toda la información con fuentes de confianza para asegurarse de que ésta sea completa y acorde con los estándares aceptados en el momento de la publicación. Sin embargo, en vista de la posibilidad de un error humano o cambios en las ciencias médicas, ni los autores, ni la editorial, o cualquier otra persona implicada en la preparación o la publicación de este trabajo, garantizan que la totalidad de la información aquí contenida sea exacta o completa y no se responsabilizan de errores u omisiones o de los resultados obte- nidos del uso de esta información. Se aconseja a los lectores confirmarla con otras fuentes. Por ejemplo, y en particular, se recomienda a los lectores revisar el pros- pecto de cada fármaco que planean administrar para cerciorarse de que la información contenida en este libro sea correcta y que no se hayan producido cambios en las dosis sugeridas o en las contraindicaciones para su administración. Esta recomendación cobra especial importancia respecto a fármacos nuevos o de uso infre- cuente. Los Editores han hecho todos los esfuerzos para localizar a los titulares del copyright del material fuente utilizado por el autor. Si por error u omisión no se ha citado a algún titular, se subsanará en la próxima reimpresión. Gracias por comprar el original. Esta monografía es producto del esfuerzo de profesionales como usted, o de sus profesores, si usted es estudiante. Tenga en cuenta que fotocopiarlo es una falta de respeto hacia ellos y un robo de sus derechos intelectuales. EDITORIAL MEDICA ESPAÑA Alberto Alcocer, 24, 6.º piso - 28036 Madrid, España Tel.: (34-91) 1317800 / Fax: (34-91) 1317805 Visite nuestra página web: e-mail: [email protected] http://www.medicapanamericana.com MÉXICO Hegel 141 2.º Piso. Colonia Chapultepec Morales Delegación Miguel Hidalgo - 11570 - México D.F. - México Tel.: (52-55) 5262-9470 / Fax: (52-55) 2624-2827 ARGENTINA e-mail: [email protected] Marcelo T. de Alvear 2.145 (C 1122 AAG) - Ciudad Autónoma de Buenos Aires, Argentina Tel.: (54-11) 4821-2066 / Fax: (54-11) 4821-1214 VENEZUELA e-mail: [email protected] Edificio Polar, Torre Oeste, Piso 6, Of. 6-C Plaza Venezuela, Urbanización Los Caobos, COLOMBIA Parroquia El Recreo, Municipio Libertador - Caracas Depto. Capital - Venezuela Carrera 7a A Nº 69-19 - Santa Fe de Bogotá DC - Colombia. Tel.: (58-212) 793-2857/6906/5985/1666 Tel.: (57-1) 235-4068 / Fax: (57-1) 345-0019 Fax: (58-212) 793-5885 e-mail: [email protected] e-mail: [email protected] ISBN: 978-84-7903-899-1 ISBN-10: 84-7903-899-3 Todos los derechos reservados. Este libro o cualquiera de sus partes no podrán ser reproducidos ni archivados en sistemas recuperables, ni transmitidos en ninguna forma o por ningún medio, ya sean mecánicos, electrónicos, fotocopiadoras, grabaciones o cualquier otro, sin el permiso previo de Editorial Médica Panamerica- na, S. A. © 2008, Sociedad Española de Radiología Médica (SERAM) © 2008, EDITORIAL MÉDICA PANAMERICANA, S. A. Alberto Alcocer, 24 - 28036 Madrid Depósito Legal: M. 38043- 2006 Impreso en España Libro SERAM-2007 13/11/07 12:40 Página V Índice de autores José María Alústiza Echeverría Javier Lafuente Martínez Unidad Osatek. San Sebastián. Servicio de Radiodiagnóstico. Hospital General Universitario Gregorio Marañón. Madrid. Amaia Arrillaga Hermoso Unidad Osatek. San Sebastián. Ángel Lancharro Zapata Servicio de Radiodiagnóstico. Joaquim Barceló Obregón Hospital General Universitario Gregorio Marañón. Madrid. Departamento de Resonancia Magnética. Clínica Girona. Girona. Teresa Marcuello Peña Servicio de Radiodiagnóstico. Anna Darnell Martín Hospital Universitario Miguel Servet. Zaragoza. Unidad de Diagnóstico por la Imagen de Alta Tecnología (UDIAT). Luis Martí-Bonmatí Corporación Sanitaria del Parc-Taulí. Sabadell. Barcelona. Servicio de Radiología Eduardo Fraile Moreno Hospital Universitario Dr. Peset. Valencia. Servicio de Radiodiagnóstico. Hospital Quirón Valencia. Hospital Universitario Príncipe de Asturias. Julio Martín Martínez Departamento Especialidades Médicas. Unidad de Diagnóstico por la Imagen de Alta Tecnología (UDIAT). Facultad de Medicina. Universidad de Alcalá. Corporación Sanitaria del Parc-Taulí. Sabadell. Barcelona. Ramón Galbe Sada Cristina Méndez Díaz Servicio de Radiodiagnóstico. Hospital Universitario Miguel Servet. Servicio de Radiología. Zaragoza. Complejo Hospitalario Universitario Juan Canalejo. La Coruña. Laura García del Salto Lorente Ramiro Méndez Fernández Servicio de Radiodiagnóstico. Servicio de Radiología. Hospital Universitario Príncipe de Asturias. Hospital Clínico San Carlos. Madrid. Departamento Especialidades Médicas. Ángel Morales Santos Facultad de Medicina. Universidad de Alcalá. Servicio de Radiología. Eduardo Manuel Gil Martínez Hospital Donostia. San Sebastián. Centro Pet Cartuja. Sevilla. David Moratal Pérez Isabel González Álvarez Servicio de Radiología. Hospital Quirón Valencia. Servicio de Radiología. Universidad Politécnica de Valencia. Hospital Universitario San Juan. Alicante. Francisco Moya García Pedro González Cabezas Centro Pet Mediterráneo. Alicante. Centro Pet Salud. Valencia. Yolanda Pallardó Calatayud Cristina González Sainza Servicio de Radiología. Unidad Osatek. San Sebastián. Hospital de la Ribera. Alzira. Lucía Graña López Jordi Puig Domingo Servicio de Radiología. Servicio de Diagnóstico por Imagen UDIAT CD. Hospital Clínico San Carlos. Madrid. Corporació Sanitaria Parc Taulí. Sabadell. Barcelona. Libro SERAM-2007 13/11/07 12:40 Página VI VI MEDIOS DE CONTRASTE EN RADIOLOGÍA Tomás Ripollés González Rafaela Soler Fernández Servicio de Radiología. Hospital Universitario Dr. Peset. Servicio de Radiología. Valencia. Complejo Hospitalario Universitario Juan Canalejo. La Coruña. Esther Rodríguez García Antonio Talegón Meléndez Servicio de Radiología. Servicio de Radiología. Hospital Virgen del Rocío. Complejo Hospitalario Universitario Juan Canalejo. Sevilla. La Coruña. Carmen Tirado Bejarano Ricardo Rodríguez González Servicio de Radiodiagnóstico. Servicio de Radiología. Hospital General Universitario Gregorio Marañón. Hospital Clínico San Carlos. Madrid. Madrid. Luis H. Ros Mendoza Joan Carles Vilanova Busquets Servicio de Radiodiagnóstico. Departamento de Resonancia Magnética. Hospital Universitario Miguel Servet. Clínica Girona. Girona. Zaragoza. Juan Vieito Fuentes Roberto Sanz Requena Servicio de Radiología. Servicio de Radiología. Hospital Quirón Valencia. Complejo Hospitalario Universitario de Vigo. Pontevedra. Libro SERAM-2007 13/11/07 12:40 Página VII Índice Introducción a los medios de contraste en Radiología................................................ 1 Luis Martí-Bonmatí y Yolanda Pallardó Calatayud Capítulo 1. Medios de contraste yodados iónicos: moléculas y propiedades ............................... 3 Eduardo Fraile Moreno y Laura García del Salto Lorente Capítulo 2. Medios de contraste yodados no iónicos ....................................................................... 9 Javier Lafuente Martínez, Ángel Lancharro Zapata y Carmen Tirado Bejarano Capítulo 3. Medios de contraste basados en gadolinio de distribución extracelular.................. 21 Rafaela Soler Fernández, Esther Rodríguez García y Cristina Méndez Díaz Capítulo 4. Medios de contraste de distribución intracelular y mixta .......................................... 35 Julio Martín Martínez y Anna Darnell Martín Capítulo 5. Medios de contraste basados en gadolinio de distribución intravascular ................ 47 Joan Carles Vilanova Busquets y Joaquim Barceló Obregón Capítulo 6. Medios de contraste y radiofármacos en la PET-TC .................................................... 55 Francisco Moya García, Eduardo Manuel Gil Martínez y Pedro González Cabezas Capítulo 7. Contrastes superparamagnéticos en la resonancia magnética.................................. 67 José María Alústiza Echeverría, Amaia Arrillaga Hermoso y Cristina González Sainza Capítulo 8. Medios de contraste por ecografía ................................................................................. 77 Jordi Puig Domingo, Tomás Ripollés González y Antonio Talegón Meléndez Capítulo 9. Contrastes enterales........................................................................................................
Load more

Recommended publications
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • 1488 Contrast Media
    1488 Contrast Media Metrizoic Acid (BANM, rINNM) form microbubbles of perflenapent gas that provide echo- be diluted in 50 mL of sodium chloride 0.9% and given by intra- enhancement. A small amount of perflisopent (below) was also venous infusion at an initial rate of 4 mL/minute, adjusted as re- Acide Métrizoïque; Ácido metrizoico; Acidum Metrizoicum; included in the formulation. quired, to a maximum rate of 10 mL/minute. Metritsoiinihappo; Metrizoinsyra. 3-Acetamido-2,4,6-tri-iodo-5- (N-methylacetamido)benzoic acid. ◊ References. Serious cardiopulmonary reactions, including fatalities, have been reported with perflutren and it should be used with extreme Метризоевая Кислота 1. Robbin ML, Eisenfeld AJ. Perflenapent emulsion: a US contrast agent for diagnostic radiology—multicenter, double-blind com- caution in patients with pulmonary hypertension or unstable car- C12H11I3N2O4 = 627.9. parison with a placebo. Radiology 1998; 207: 717–22. diopulmonary conditions. The safety of perflutren has not been CAS — 1949-45-7. 2. Kitzman DW, Wesley DJ. Safety assessment of perflenapent established in patients with right-to-left cardiac shunts; it should ATC — V08AA02. emulsion for echocardiographic contrast enhancement in pa- also be used with extreme caution or avoided in such patients. tients with congestive heart failure or chronic obstructive pulmo- Perflutren has also been given by intra-ocular injection to pro- ATC Vet — QV08AA02. nary disease. Am Heart J 2000; 139: 1077–80. vide tamponade in the management of retinal detachment. Adverse effects. References. H C 3 1. Herzog CA. Incidence of adverse events associated with use of Perflexane (USAN, rINN) NH I O perflutren contrast agents for echocardiography.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0184642 A1 Bartling Et Al
    US 2012O184642A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0184642 A1 Bartling et al. (43) Pub. Date: Jul.19, 2012 (54) MULTIMODAL VISIBLE POLYMER (30) Foreign Application Priority Data EMBOLIZATION MATERAL Jul. 7, 2009 (DE) ......................... 102O09.0321.89.6 (76) Inventors: Soenke Bartling, Heidelberg (DE); O O Shlomo Margel, Rehovot (IL); Publication Classification Hagit Aviv, Givart Shmuel (IL) (51) Int. Cl. A6IL 3L/04 (2006.01) (21) Appl. No.: 13/382,352 A6IL 3L/06 (2006.01) A6IL 3 L/18 (2006.01) (22) PCT Filed: Jul. 6, 2010 (52) U.S. Cl. ........................................................ 523/113 (57) ABSTRACT (86). PCT No.: PCT/EP2010/059631 The present invention relates to embolization material for S371 (c)(1), therapeutic use, wherein said material is visible via more than (2), (4) Date: Mar. 23, 2012 one imaging technique. Patent Application Publication Jul. 19, 2012 Sheet 1 of 19 US 2012/O184642 A1 8 3 x 8888: 83 x 38 : Patent Application Publication Jul. 19, 2012 Sheet 2 of 19 US 2012/O184642 A1 Patent Application Publication Jul. 19, 2012 Sheet 3 of 19 US 2012/O184642 A1 & S S S S S SS &S & S& SS S S & S S Patent Application Publication Jul. 19, 2012 Sheet 4 of 19 US 2012/O184642 A1 Patent Application Publication Jul. 19, 2012 Sheet 5 of 19 US 2012/O184642 A1 38 : x3.3 8:::::::::::::::: Patent Application Publication Jul.19, 2012 Sheet 6 of 19 US 2012/0184642 A1 Patent Application Publication Jul. 19, 2012 Sheet 7 of 19 US 2012/O184642 A1 Patent Application Publication Jul.
    [Show full text]
  • Book of Abstracts
    BBBOOOOOOKKK OOOFFF AAABBBSSSTTTRRRAAACCCTTTSSS ESUR 06© Welcome To Egypt & ESUR 06... Dear Friends, We warmly welcome you to attend the 13th European Symposium on Urogenital Radiology, ESUR 2006... The symposium will start by the Member's day on September 8th. The programme includes post graduate course, workshops, scientific papers and posters. The main topic of the Symposium is Imaging of genitourinary tumors. Also, interesting topics on modern Urogenital Imaging will be presented. The Organizing Committee is delighted to welcome you to the ESUR Cairo meeting in September 2006. Tarek El-Diasty, MD Chairman of the Organizing Committee Of ESUR 06 Symposium © European Sociatey of Urogenital Radiology ESUR 06 Abstract book Under the Patronage of Her Excellency Mrs. Suzanne Mubarak HONOUR COMMITTEE Minister of High Education and Scientific Research Minister of Health & Population Minister of Tourism Mayor of the City of Cairo ESUR BOARD President: Lorenzo L.E. Derchi (I) President Elect: Sameh K. Morcos (UK) Secretary: Gertraud Heinz-Peer (A) Past President: Jelle O. Barentsz (NL) Member-at-Large: Andres Magnusson (S) PROGRAM COMMITTEE Lorenzo Derchi (I) Sami Moussa (UK) Gertraud Heinz-Peer (A) Karen Kinkel (CH) Jelle Barentsz (NL) Ullrich Mueller-Lisse (DE) Olivier Helenon (F) Richard Cohan (USA) Philip Kenney (USA) Anders Magnusson (S) Henrik Thomsen (DK) Darja Babnik Peskar (SI) Tarek El-Diasty (EG) LOCAL COMMITTEE Tarek El-Diasty Mohamed Abo El-Ghar Sameh Hanna Essam Abou Bieh Hossam Gad Nadine Barsoum Hany Samy Rania Farouk El Sayed
    [Show full text]
  • Atc Index 2010
    ATC INDEX 2010 This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name. 287 A L 04 A B 04 Adalimumab A 03 A B 16 (2-benzhydryloxyethyl) D 10 A D 03 Adapalene diethyl-methylammonium iodide D 10 A D 53 Adapalene, combinations D 01 A E 06 2-(4-chlorphenoxy)- ethanol J 05 A F 08 Adefovir dipivoxil V 03 A B 27 4-dimethylaminophenol A 16 A A 02 Ademetionine J 05 A F 06 Abacavir C 01 E B 10 Adenosine L 02 B X 01 Abarelix N 05 B A 07 Adinazolam L 04 A A 24 Abatacept V 08 A C 04 Adipiodone B 01 A C 13 Abciximab N 06 B X 17 Adrafinil L 04 A A 22 Abetimus A 01 A D 06 Adrenalone B 02 B C 01 Absorbable gelatin sponge B 02 B C 05 Adrenalone C 01 E B 13 Acadesine L 04 A B 03 Afelimomab N 07 B B 03 Acamprosate A 16 A B 03 Agalsidase alfa A 10 B F 01 Acarbose A 16 A B 04 Agalsidase beta C 07 A B 04 Acebutolol A 11 A H Agents for atopic dermatitis, excluding C 07 B B 04 Acebutolol and thiazides corticosteroids S 01 E B 08 Aceclidine N 06 A X 22 Agomelatine S 01 E B 58 Aceclidine, combinations C 01 B A 05 Ajmaline M 01 A B 16 Aceclofenac B 05 X B 02 Alanyl glutamine M 02 A A 25 Aceclofenac N 06 A B 07 Alaproclate R 03 D A 09 Acefylline piperazine P 02 C A 03 Albendazole M 01 A B 11 Acemetacin B 05 A A 01 Albumin B 01 A A 07 Acenocoumarol A 07 X A 01 Albumin tannate N 05 A A 04 Acepromazine
    [Show full text]
  • Wo 2011/003902 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 13 January 2011 (13.01.2011) WO 2011/003902 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 49/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/EP2010/05963 1 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 6 July 2010 (06.07.2010) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 10 2009 032 189.6 7 July 2009 (07.07.2009) DE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventor; and GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant : BARTLING, Soenke [DE/DE]; Bussemer- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, gasse 20, 691 17 Heidelberg (DE).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,383,152 B2 Jans Et Al
    USOO8383152B2 (12) United States Patent (10) Patent No.: US 8,383,152 B2 Jans et al. (45) Date of Patent: Feb. 26, 2013 (54) PHARMACEUTICAL DOSAGE FORM (58) Field of Classification Search .................. 424/468, 424/464, 474: 514/654 (75) Inventors: Eugeen Marie Jozef Jans, Meerhout See application file for complete search history. (BE); Filip René Irena Kiekens, Geel (BE); Jody Firmin Marceline (56) References Cited Voorspoels, Reningelst (BE); Anne U.S. PATENT DOCUMENTS Faure, Vosselaar (BE); Elisabeth 3,806,603 A 4, 1974 Gaunt et al. Arkenau-Maric, Köln (DE); Lutz 3,865,108 A 2/1975 Hartop Barnscheid, Mönchengladbach (DE); 3,966,747 A 6, 1976 Monkovic et al. Johannes Bartholomäus, Aachen (DE); 3,980,766 A 9, 1976 Shaw et al. 4,002,173 A 1/1977 Manning et al. Marc Frevel, Monschau (DE); Eric 4,014,965 A 3, 1977 Stube et al. Galia, Inden (DE); Iris Ziegler, Neusaf 4,070,494 A 1/1978 Hoffmeister et al. (DE); Andrea Schissele, Berlin (DE) (Continued) (73) Assignee: Gruenenthal GmbH, Anchen (DE) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this AR 46994 12, 2004 patent is extended or adjusted under 35 AR O45.353 10/2005 U.S.C. 154(b) by 368 days. (Continued) (21) Appl. No.: 12/358,415 OTHER PUBLICATIONS El-Egakey, Adeletal, Pharmacerutica Acta Helvetiae, vol. 46, Mar. (22) Filed: Jan. 23, 2009 19, 1970. (65) Prior Publication Data (Continued) US 2009/0202634 A1 Aug. 13, 2009 Primary Examiner — Aradhana Sasan (74) Attorney, Agent, or Firm — Norris McLaughlin & (30) Foreign Application Priority Data Marcus, P.A.
    [Show full text]